Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03178851
Title Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

melanoma

Therapies

Atezolizumab

Atezolizumab + Cobimetinib

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST